Clinical Trial Detail

NCT ID NCT01781026
Title Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Yale University
Indications

melanoma

Therapies

Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST